Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139253

Published: 2020

Journal Articles

Quantitative Analysis of Tumor-Specific BCL2 Expression in DLBCL: Refinement of Prognostic Relevance of BCL2

Jin Roh, Hyungwoo Cho, MD, Dok Hyun Yoon, Jung Yong Hong, A-Neum Lee, Hyeon-Seok Eom, Hyewon Lee, MD, Weon Seo Park, Jae Ho Han, MD, Seong Hyun Jeong, Joon Seong Park, MD, Hyo-Kyung Pak, So-Woon Kim, MD, Sang-Yeob Kim, Cheolwon Suh, Jooryung Huh, Chan-Sik Park

Blood (2019) 134 (Supplement_1): 2901.

https://doi.org/10.1182/blood-2019-130279

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

WHO2016 Vs. WHO2008 Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia

Sung-Ran Cho, MD, Joon Seong Park, MD, Yeonsook Moon, MD, Mi Hyang Kim, MD, Jeong-Yeal Ahn, MD, Jungwon Huh, MD, Hye Ryoun Kim, MD PhD, Jae Ho Han, MD

Blood (2017) 130 (Supplement 1): 5314.

https://doi.org/10.1182/blood.V130.Suppl_1.5314.5314

Published: 2017

Journal Articles

Effect of Early Removal of Central Catheterization in Febrile Neutropenic Patients with Acute Leukemia

Su Hyun Hwang, MD, Yong Won Choi, MD, Seong Hyun Jeong, MD, Joon Seong Park, MD

Blood (2015) 126 (23): 4895.

https://doi.org/10.1182/blood.V126.23.4895.4895

Published: 2015

Journal Articles

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Blood (2014) 124 (21): 3155.

https://doi.org/10.1182/blood.V124.21.3155.3155

Published: 2014

Journal Articles

Clinical Benefit of Maintenance Chemotherapy in Patients with Acute Myeloid Leukemia

Yong Won Choi, MD, Joon Seong Park, MD, Mi Sun Ahn, MD, Hyun Woo Lee, MD, Seok Yun Kang, MD, Jin-Hyuk Choi, MDPhD, Seong Hyun Jeong, MD

Blood (2014) 124 (21): 3677.

https://doi.org/10.1182/blood.V124.21.3677.3677

Published: 2014

Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 1816.

https://doi.org/10.1182/blood.V124.21.1816.1816

Published: 2014

Journal Articles

a Randomized, Controlled, Prospective Study for Efficacy of Micafungin Versus Itraconazole As Empirical Antifungal Therapy for Febrile Neutropenic Patients with Acute Leukemia

Seong Hyun Jeong, MD, Dae Young Kim, Jun Ho Jang, Yeung-Chul Mun, Sung-Hyun Kim, Chul Won Choi, Jin Seok Kim, Joon Seong Park, MD

Blood (2014) 124 (21): 3729.

https://doi.org/10.1182/blood.V124.21.3729.3729

Published: 2014

Journal Articles

Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation

Blood (2013) 122 (21): 5379.

https://doi.org/10.1182/blood.V122.21.5379.5379

Published: 2013

Journal Articles

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Soo-Young Choi, Sung-Eun Lee, M.D., Yun Jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD, PhD, Sang Kyun Sohn, MD, PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD, PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 1499.

https://doi.org/10.1182/blood.V122.21.1499.1499

Published: 2013

Journal Articles

FactorVIII Gene Modifications Observed in Acquired Hemophilia.

Sung Ho Hwang, Hugh C Kim, M.D., Jeonga Lim, Hyun Woo Lee, M., D., Seong Hyun Jeong, Joon Seong Park, MD, Hye Sun Kim, PhD

Blood (2009) 114 (22): 4450.

https://doi.org/10.1182/blood.V114.22.4450.4450

Published: 2009

Journal Articles

The Effect of Bortezomib On Bone Metabolism of Patients with Multiple Myeloma: a Korean Multicenter Prospective Study.

Chang-Ki Min, MD, Seok Jin Kim, MD, Je-Jung Lee, MD, Cheolwon Suh, MD, Jin Seok Kim, MD, Sung-Soo Yoon, MD, Byung Soo Kim, MD, Hye Jin Kang, MD, Young Jin Choi, MD, Cheol Soo Kim, MD, Yang Soo Kim, MD, Jae-Yong Kwak, MD, Yoo Jin Kim, MD, Young Don Joo, MD, Yeung-Chul Mun, MD, Deog Yeon Jo, MD, Joon Seong Park, MD, Chi-Young Park, MD, Sung Hyun Kim, MD

Blood (2009) 114 (22): 4871.

https://doi.org/10.1182/blood.V114.22.4871.4871

Published: 2009

Journal Articles

Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).

Blood (2009) 114 (22): 4881.

https://doi.org/10.1182/blood.V114.22.4881.4881

Published: 2009

Journal Articles

Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.

Joon Seong Park, MD, Dong Hwan Kim, MD, PhD, Chul Won Choi, MD, PhD, Seong Hyun Jeong, MD, Jin-Hyuk Choi, MD, PhD, Kihyun Kim, MD, PhD, Seok Jin Kim, MD, PhD, Chul Won Jung, MD, PhD, Deok-Hwan Yang, MD, Hugh Chul Kim, MD, Jun Ho Jang, MD, PhD

Blood (2009) 114 (22): 4661.

https://doi.org/10.1182/blood.V114.22.4661.4661

Published: 2009

Journal Articles

Viability of CD34+ Cells in Cryopreserved Cord Blood

Young-woo Eom, Seong Hyun Jeong, Jin-Hyuk Choi, Seok Yun Kang, Hyun Woo Lee, Mal Sook Yang, Hyo Eun Kim, In Keun Jang, Jong Eun Lee, Yeong Jin Kim, Hugh Chul Kim, Yoon Ho Hwang, Mi Sun Ahn, Joon Seong Park, MD

Blood (2008) 112 (11): 4138.

https://doi.org/10.1182/blood.V112.11.4138.4138

Published: 2008

Journal Articles

Statistical Correlations Between Quantifiable Disease Variables and Prognosis in Hematological Malignancy Patients Treated with Itraconazole as An Empirical Antifungal Therapy: A Prospective Multicenter Observational Study in Korea

Jin Seok Kim, Ho Jin Shin, June-Won Cheong, Jong Wook Lee, Kyoo Hyung Lee, MD, Deok-Hwan Yang, Won-Sik Lee, MD, Hawk Kim, Joon Seong Park, MD, Sung Hyun Kim, MD, PhD, Sang Min Lee, Eun-Kee Song, Yee Soo Chae, Jinny Park, Young Rok Do, M.D., Yoo Hong Min

Blood (2008) 112 (11): 4028.

https://doi.org/10.1182/blood.V112.11.4028.4028

Published: 2008

Journal Articles

Effect of Aging on Host Dendritic Cell (DC) Numbers and Function, and Response to Regulatory DC Treatment in a Murine Allogeneic Transplant Model.

Annette J. Schlueter, MD, PhD, Joon Seong Park, MD, Werner W. Wilke, MD, PhD, Ji Fan, MD, PhD, Roger D. Gingrich, MD, PhD

Blood (2006) 108 (11): 3244.

https://doi.org/10.1182/blood.V108.11.3244.3244

Published: 2006

NARROW

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Quantitative Analysis of Tumor-Specific BCL2 Expression in DLBCL: Refinement of Prognostic Relevance of BCL2

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

WHO2016 Vs. WHO2008 Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia

Effect of Early Removal of Central Catheterization in Febrile Neutropenic Patients with Acute Leukemia

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Clinical Benefit of Maintenance Chemotherapy in Patients with Acute Myeloid Leukemia

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

a Randomized, Controlled, Prospective Study for Efficacy of Micafungin Versus Itraconazole As Empirical Antifungal Therapy for Febrile Neutropenic Patients with Acute Leukemia

Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

FactorVIII Gene Modifications Observed in Acquired Hemophilia.

The Effect of Bortezomib On Bone Metabolism of Patients with Multiple Myeloma: a Korean Multicenter Prospective Study.

Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).

Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.

Viability of CD34+ Cells in Cryopreserved Cord Blood

Statistical Correlations Between Quantifiable Disease Variables and Prognosis in Hematological Malignancy Patients Treated with Itraconazole as An Empirical Antifungal Therapy: A Prospective Multicenter Observational Study in Korea

Effect of Aging on Host Dendritic Cell (DC) Numbers and Function, and Response to Regulatory DC Treatment in a Murine Allogeneic Transplant Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only